Genomic abnormalities by CD30 and their roles in the tumorigenic process of Epstein-Barr virus-infected cells

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K07442
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 49020:Human pathology-related
• Research Institution: Kitasato University
• Principal Investigator: WATANABE Mariko 北里大学, 医療衛生学部, 助教 (90270701)
• Co-Investigator(Kenkyū-buntansha): 堀江 良一 北里大学, 医療衛生学部, 教授 (80229228)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: Epstein―Barr virus (EBV) / リンパ芽球様細胞株（LCL） / CD30

Outline of Final Research Achievements

Epstein-Barr virus (EBV) infection is closely related to the occurrence of malignant lymphomas. CD30 stimulation did not induce apparent changes related to genomic abnormalities in lymphoblastoid cell lines (LCLs). On the other hand, classical Hodgkin lymphoma (cHL) cell lines, which represent transformed statuses of LCLs revealed genomic abnormalities by CD30 stimulation. CD30 mediated generation of reactive oxygen species (ROS) was thought to play causative roles in the generation of genomic abnormalities. The results suggest that LCL and cHL cells appear to show different responses to ROS. The results in this study suggest that additional changes in cellular statuses are required to trigger CD30 mediated induction of genomic abnormalities in early stage of EBV-infected cells.

Free Research Field

血液病理学

Academic Significance and Societal Importance of the Research Achievements

Epstein-Barr virus (EBV) 感染が悪性リンパ腫の発症原因であることはよく知られている。本研究の結果はEBV感染初期の細胞にさらに付加的な異常が加わった状態ではCD30 刺激がゲノム異常の誘発を起こす可能性があることを示唆している。EBV感染細胞は病態が進むとリンパ増殖性疾患（LPD）から悪性リンパ腫へと進展する。さらなる検討は必要であるが、進行性のLPDは悪性リンパ腫発症予防の見地からもアウリスタチン E 付加抗 CD30 抗体（ブレンツキシマブベドチン）による CD30 を分子標的とした治療の対象となりうると考えられる。